JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, vol.142, no.12, pp.2429-2446, 2016 (Journal Indexed in SCI)
Article / Review
Title of Journal :
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Cancer, Drug conjugate, Monoclonal antibody, Peptide, Target therapy, Tumor, Tyrosine kinase receptor, MACROPHAGE-STIMULATING PROTEIN, HEPATOCYTE GROWTH-FACTOR, DORIGINE NANTAIS RON, HUMAN MONOCLONAL-ANTIBODIES, COLORECTAL-CARCINOMA CELLS, RESISTANT PROSTATE-CANCER, HUMAN-HUMAN HYBRIDOMAS, INHIBITS TUMOR-GROWTH, HUMAN GASTRIC-CANCER, BREAST-CANCER
Cancer is one of the most important life-threatening diseases in the world. The current efforts to combat cancer are being focused on molecular-targeted therapies. The main purpose of such approaches is based on targeting cancer cell-specific molecules to minimize toxicity for the normal cells. RON (Recepteur d'Origine Nantais) tyrosine kinase receptor is one of the promising targets in cancer-targeted therapy and drug delivery.